ARTICLE | Finance
Tricida: Ilypsa 3.0?
How CKD play Tricida could be following the Relypsa/Ilypsa game plan
August 1, 2016 7:00 AM UTC
Although both Tricida Inc. and one of its investors are keeping tight-lipped about the biotech's technology and development plans, it appears both are hoping Tricida is the next version of Relypsa Inc. (NASDAQ:RLYP) and its predecessor Ilypsa Inc. - a chronic kidney disease (CKD) play that can quickly develop a single asset to market.
On July 25, Tricida raised $55 million in a series C round led by new investor Longitude Capital. New investor Vivo Capital also participated, as did existing investors OrbiMed Advisors, Sibling Capital Ventures and Limulus Venture Partners...